Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonoset...
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
About this item
Full title
Author / Creator
Publisher
Dove Medical Press
Journal title
Language
English
Formats
Publication information
Publisher
Dove Medical Press
Subjects
More information
Scope and Contents
Contents
Vito Lorusso National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy Abstract: As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 receptor antagonist (RA) with an NK1-RA. Moreover, the major predictors of acute and...
Alternative Titles
Full title
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3c39702f6a394bf182ae261b8e35cd5e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3c39702f6a394bf182ae261b8e35cd5e
Other Identifiers
ISSN
1178-203X
